{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:11Z","timestamp":1791216731839,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016819","name":"Octapharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014255","name":"Fonds de dotation CSL Behring pour la recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014255","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014935","name":"BioCryst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic sclerosis (SSc) is the most severe systemic autoimmune disease with currently no cure. Intravenous immunoglobulins (IVIg) are an attractive candidate in this disease to counteract inflammation and fibrosis but data are scarce and conflicting. This study, assessed the effects of IVIg in a murine HOCl-induced model of SSc. We showed that IVIg prevented skin inflammation and fibrosis, by mitigating the immune cell infiltration (<jats:italic>p<\/jats:italic>\u2009=\u20090.04), proinflammatory cytokines gene overexpression (IL1\u03b2, <jats:italic>p<\/jats:italic>\u2009=\u20090.04; TNF\u03b1, <jats:italic>p<\/jats:italic>\u2009=\u20090.04; IL6, <jats:italic>p<\/jats:italic>\u2009=\u20090.05), skin and dermal thickening (<jats:italic>p<\/jats:italic>\u2009=\u20090.003 at d21 and <jats:italic>p<\/jats:italic>\u2009=\u20090.0003 at d42), the expression markers of fibrosis, such as \u03b1SMA (<jats:italic>p<\/jats:italic>\u2009=\u20090.031 for mRNA and <jats:italic>p<\/jats:italic>\u2009=\u20090.05 for protein), collagen (<jats:italic>p<\/jats:italic>\u2009=\u20090.05 for mRNA and <jats:italic>p<\/jats:italic>\u2009=\u20090.04 for protein, <jats:italic>p<\/jats:italic>\u2009=\u20090.05 for the hydroxyproline content) and fibronectin (<jats:italic>p<\/jats:italic>\u2009=\u20090.033 for mRNA). Moreover, IVIg prevented HOCl-induced alterations in splenic cell homeostasis. When administered in curative mode, despite their ability to reduce skin and dermal thickness (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001 and <jats:italic>p<\/jats:italic>\u2009=\u20090.0002), IVIg showed partial or more mixed effects on skin inflammation and established fibrosis. These data favor further clinical trials in SSc patients on the potential efficiency of early and\/or repeated IVIg administration.<\/jats:p>","DOI":"10.1038\/s41598-023-42464-9","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T18:02:13Z","timestamp":1694541733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-3329","authenticated-orcid":false,"given":"Silvia","family":"Speca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9098-4984","authenticated-orcid":false,"given":"Meryem-Maud","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1047-1274","authenticated-orcid":false,"given":"Manel","family":"Jendoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-9405","authenticated-orcid":false,"given":"Thomas","family":"Guerrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-411X","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Sanges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-4212","authenticated-orcid":false,"given":"Delphine","family":"Staumont-Sall\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7432-847X","authenticated-orcid":false,"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-3719","authenticated-orcid":false,"given":"Sylvain","family":"Dubucquoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-2441","authenticated-orcid":false,"given":"Vincent","family":"Sobanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8279-1912","authenticated-orcid":false,"given":"Aurore","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-1817","authenticated-orcid":false,"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"42464_CR1","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore, Y. et al. Systemic sclerosis. Nat. Rev. Dis. Primers 1, 15002 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"42464_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s12026-017-8926-y","volume":"65","author":"M Furue","year":"2017","unstructured":"Furue, M. et al. Pathogenesis of systemic sclerosis-current concept and emerging treatments. Immunol. Res. 65, 790\u2013797 (2017).","journal-title":"Immunol. Res."},{"key":"42464_CR3","first-page":"125","volume":"72","author":"D Khanna","year":"2020","unstructured":"Khanna, D. et al. Abatacept in early diffuse cutaneous systemic sclerosis\u2014Results of a phase 2 investigator-initiated, multicenter. Double Blind Randomized Placebo Control. Trial. Arthritis Rheumatol. 72, 125\u2013136 (2020).","journal-title":"Double Blind Randomized Placebo Control. Trial. Arthritis Rheumatol."},{"key":"42464_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12026-014-8615-z","volume":"61","author":"L Cantarini","year":"2014","unstructured":"Cantarini, L. et al. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunol. Res. 61, 326\u2013337 (2014).","journal-title":"Immunol. Res."},{"key":"42464_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.clim.2010.01.001","volume":"135","author":"D Paquin Proulx","year":"2010","unstructured":"Paquin Proulx, D., Aubin, \u00c9., Lemieux, R. & Bazin, R. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin. Immunol. 135, 422\u2013429 (2010).","journal-title":"Clin. Immunol."},{"key":"42464_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10238-005-0079-y","volume":"5","author":"A Ephrem","year":"2005","unstructured":"Ephrem, A. et al. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin. Exper. Med. 5, 135\u2013140 (2005).","journal-title":"Clin. Exper. Med."},{"key":"42464_CR7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/art.10363","volume":"46","author":"M Blank","year":"2002","unstructured":"Blank, M. et al. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum. 46, 1689\u20131690 (2002).","journal-title":"Arthritis Rheum."},{"key":"42464_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2249.2010.04295.x","volume":"163","author":"M Kajii","year":"2011","unstructured":"Kajii, M. et al. Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma. Clin. Exp. Immunol. 163, 235\u2013241 (2011).","journal-title":"Clin. Exp. Immunol."},{"key":"42464_CR9","first-page":"151","volume":"31","author":"K Takehara","year":"2013","unstructured":"Takehara, K., Ihn, H. & Sato, S. A randomized, double-blind, placebo-controlled trial: Intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin. Exp. Rheumatol. 31, 151\u2013156 (2013).","journal-title":"Clin. Exp. Rheumatol."},{"key":"42464_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/art.20195","volume":"50","author":"Y Levy","year":"2004","unstructured":"Levy, Y. et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: An open-label study. Arthritis Rheum. 50, 1005\u20131007 (2004).","journal-title":"Arthritis Rheum."},{"key":"42464_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3899\/jrheum.140833","volume":"42","author":"CL Poelman","year":"2015","unstructured":"Poelman, C. L. et al. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J. Rheumatol. 42, 236\u2013242 (2015).","journal-title":"J. Rheumatol."},{"key":"42464_CR12","doi-asserted-by":"publisher","first-page":"102981","DOI":"10.1016\/j.autrev.2021.102981","volume":"20","author":"E Agostini","year":"2021","unstructured":"Agostini, E. et al. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from systematic literature review and from real life experience. Autoimmun. Rev. 20, 102981 (2021).","journal-title":"Autoimmun. Rev."},{"key":"42464_CR13","doi-asserted-by":"publisher","first-page":"102431","DOI":"10.1016\/j.autrev.2019.102431","volume":"19","author":"B Chaigne","year":"2020","unstructured":"Chaigne, B. et al. Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients. Autoimmun. Rev. 19, 102431 (2020).","journal-title":"Autoimmun. Rev."},{"key":"42464_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.autrev.2017.02.008","volume":"16","author":"S Sanges","year":"2017","unstructured":"Sanges, S. et al. Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. Autoimmun. Rev. 16, 377\u2013384 (2017).","journal-title":"Autoimmun. Rev."},{"key":"42464_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2012.09.010","volume":"69","author":"H Kudo","year":"2013","unstructured":"Kudo, H. et al. Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients. J. Dermatol. Sci. 69, 77\u201380 (2013).","journal-title":"J. Dermatol. Sci."},{"key":"42464_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clim.2018.12.006","volume":"199","author":"JP Gomes","year":"2019","unstructured":"Gomes, J. P., Santos, L. & Shoenfeld, Y. Intravenous immunoglobulin (IVIG) in the vanguard therapy of systemic sclerosis. Clin. Immunol. 199, 25\u201328 (2019).","journal-title":"Clin. Immunol."},{"key":"42464_CR17","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/art.38627","volume":"66","author":"S-Y Lee","year":"2014","unstructured":"Lee, S.-Y. et al. Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent manner. Arthritis Rheumatol. 66, 1768\u20131778 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"42464_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab, I. & Nimmerjahn, F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 13, 176\u2013189 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"42464_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/OARRR.S50009","volume":"6","author":"CM Artlett","year":"2014","unstructured":"Artlett, C. M. Animal models of systemic sclerosis: their utility and limitations. OARRR 6, 65\u201381 (2014).","journal-title":"OARRR"},{"key":"42464_CR20","doi-asserted-by":"publisher","first-page":"e3000411","DOI":"10.1371\/journal.pbio.3000411","volume":"18","author":"NP du Sert","year":"2020","unstructured":"du Sert, N. P. et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 20. PLOS Biol. 18, e3000411 (2020).","journal-title":"PLOS Biol."},{"key":"42464_CR21","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.4049\/jimmunol.0803705","volume":"182","author":"A Servettaz","year":"2009","unstructured":"Servettaz, A. et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J. Immunol. 182, 5855\u20135864 (2009).","journal-title":"J. Immunol."},{"key":"42464_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s004030000183","volume":"292","author":"T Yamamoto","year":"2000","unstructured":"Yamamoto, T., Kuroda, M. & Nishioka, K. Animal model of sclerotic skin III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch. Dermatol. Res. 292, 535\u2013541 (2000).","journal-title":"Arch. Dermatol. Res."},{"key":"42464_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/ar.22641","volume":"296","author":"EC Jensen","year":"2013","unstructured":"Jensen, E. C. Quantitative analysis of histological staining and fluorescence using ImageJ. Anat. Rec. Hoboken 296, 378\u2013381 (2013).","journal-title":"Anat. Rec. Hoboken"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42464-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42464-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42464-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T05:24:07Z","timestamp":1700371447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42464-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42464"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-42464-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"3 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15102"}}